Published: Wed, October 11, 2017
Life&Culture | By Rose Hansen

The Case for and Against Flexion Therapeutics, Inc. (FLXN)

The Case for and Against Flexion Therapeutics, Inc. (FLXN)

Price Target plays a critical role when it comes to the analysis of a Stock.

Equity analyst Northland Securities added FLXN to its research portfolio by announcing an initial rating of "Outperform".

Flexion Therapeutics Inc had its "outperform" rating reiterated by analysts at BMO Capital Markets.

03/23/2017 - Flexion Therapeutics Inc had its "overweight" rating reiterated by analysts at Cantor Fitzgerald. Of those analysts, 4 rate stock as a Strong Buy, 0 rate it as Hold, and just no analyst rates it as a Moderate Sell. Flexion Therapeutics has $44 highest and $28.0 lowest target.

Analysts expect Flexion Therapeutics Inc (NASDAQ:FLXN) to report $-0.95 EPS on November, 6.They anticipate $0.30 EPS change or 46.15% from last quarter's $-0.65 EPS. 785,165 shares of the company traded hands. Flexion Therapeutics has a one year low of $15.93 and a one year high of $32.25. The company's market capitalization is $898.76 million. Moving toward the technical facts, its current distance from 20-Day Simple Moving Average is 11.84% and standing 17.67% away from 50-Day Simple Moving Average while traded up 30.41% from 200-Day Simple Moving Average.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Tuesday, August 8th.

Among 3 analysts covering AMN Healthcare (NYSE:AMN), 2 have Buy rating, 0 Sell and 1 Hold. In the latest earnings report the EPS was $-3.11 and is expected to be $-3.75 for the current year with 31,905,000 shares now outstanding. "(FLXN) Trading -5.4% Higher on Analyst Upgrade" was originally posted by BBNS and is the sole property of of BBNS. If you are accessing this article on another publication, it was illegally copied and republished in violation of worldwide copyright and trademark law. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company's stock valued at $54,921,000 after acquiring an additional 591,981 shares during the period. Finally, Wells Fargo & Company set a $39.00 price target on shares of Flexion Therapeutics and gave the stock a "buy" rating in a research report on Friday. After this purchase, 727,812 common shares of FLXN are directly owned by the insider, with total stake valued at $21,783,413. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Nirmala Sitharaman interacting with chinese soldiers at Nathu la pass in sikkim
Recent media reports have suggested that Chinese soldiers remain in the vicinity of the Doklam standoff site. Defense Minister Nirmala Sitharaman at Nathu La in Sikkim .

Analysts' ultimate objective when projecting revenue is to determine the appropriate value for a stock. The firm now has an "outperform" rating on the specialty pharmaceutical company's stock. Institutional investors and hedge funds own 83.26% of the company's stock.

03/30/2015 - MLV & Co began new coverage on Flexion Therapeutics Inc giving the company a "buy" rating. Raymond James Financial Services Advisors Inc. now owns 63,520 shares of the specialty pharmaceutical company's stock worth $1,284,000 after acquiring an additional 7,667 shares in the last quarter.

Amn Healthcare Services Incorporated (NYSE:AMN) had an increase of 1.32% in short interest. Wasatch Advisors Inc. raised its position in Flexion Therapeutics by 58.7% during the second quarter.

The company is expected to report earnings of $-0.95 a share for the next quarter.

As of quarter end Magee Thomson Investment Partners LLC had sold a total of 37 shares trimming its position 52.9%. Finally, BB&T Securities LLC purchased a new position in shares of Flexion Therapeutics during the second quarter valued at about $289,000. American International Group Inc. now owns 16,212 shares of the specialty pharmaceutical company's stock valued at $436,000 after purchasing an additional 5,569 shares during the last quarter.

Flexion Therapeutics' new non-opioid drug has been approved to treat knee pain, but the company will also likely explore any potential it could have for other areas of the body, its CEO told CNBC on Monday. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain.

Like this: